This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). A Phase I/II study of VCTX211 has been commenced and is currently ongoing. It originated under the partnership of CRISPR Therapeutics and ViaCyte.
The latest development comes after Lilly and Sosei Heptares signed a partnership for developing small molecules that modulate new G protein-coupled receptor targets linked to diabetes and metabolic diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.
The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.
Patient-Centric Approaches: The shift towards patient empowerment has revolutionized the way pharma brands communicate. Imagine a diabetes patient sharing their experience with Ozempicit resonates far better than generic ads. WhitePapers and Webinars: Provide HCPs with resources that dive into drug efficacy and research.
From email marketing to targeted ads, make sure every piece of communication is relevant and adds value. Example: If you’re promoting a diabetes medication, use keywords like “Type 2 diabetes treatment options” and link to authoritative sources like Pharma Marketing News. They don’t want generic ads or irrelevant emails.
For example, in the Targeting Aging with Metformin (TAME) Trial , a series of six-year studies, the diabetes drug metformin will be studied for its effects in preventing age-related conditions such as cardiovascular disease, cancer, impaired cognition, and mortality. Please check your email to download the Report.
For instance, targeting a diabetes drug like Jardiance involves identifying adults struggling with Type 2 diabetes and tailoring messages about improved glycemic control. Education and Training: Provide resources like webinars or whitepapers to engage HCPs effectively.
Rates of non-communicable diseases such as hypertension, cardiovascular disease, chronic respiratory diseases, diabetes, and cancers are also considered high throughout Africa. Consequently, there are relatively small patient pools for non-communicable diseases such as cancer, diabetes, heart disease, and Alzheimer’s.
The key points need to be communicated succinctly to capture the audience’s attention. It requires a deep understanding of medical terminology and the ability to communicate scientific information in an amazingly simple manner. It is to communicate the benefits of your brand. Let’s start with the similarities.
In recent years, first generics have improved patient access to essential treatments and offered affordable treatment options for patients with multiple sclerosis, asthma, heart disease, diabetes, and even the flu. However, business and other considerations may have an impact on how quickly a generic becomes available.
Generic drug companies have already warned that manufacturing some products will become unsustainable, and they may cease manufacturing a few, such as generic diabetes and cancer drugs. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Celnova Pharma is an Argentina-based pharmaceutical company that centres its work around rare diseases, oncology, central nervous system, diabetes and critical care. HRA RD’s new partnership will function to allow HRA RD to launch its rare disease products Ketoconazole HRA and Lysodren across Argentina, Chile and Peru.
Digital therapeutic apps are being built to help manage type 2 diabetes or assist with addiction. But then you must add in the industry skills, including management of data privacy, health-specific communication protocols such as FHIR, and a good understanding of how data flows through the healthcare system,” he adds.
The agency expanded the use of Eli Lilly’s Trulicity (dulaglutide) injection to include pediatric type 2 diabetes patients ages 10 years and older, to improve glycemic control as an adjunct to diet and exercise. The FDA passed several positive supplementary approval decisions involving younger patients.
The SGLT2 inhibitor is already approved to treat type 2 diabetes (T2D), chronic kidney disease (CKD), and heart failure with reduced ejection fraction (HFrEF) in patients with or without T2D. A few weeks later, the EC extended the approval label of AstraZeneca’s Forxiga (dapagliflozin) to include the treatment of symptomatic hearth failure.
For example, if you develop a medicine that can treat diabetes and you desire FDA approval, the path is standardized and clearly laid out. For this paper, our contribution focused on the clinical evidence quality section and some of the clinical trial design components. In the U.S.,
For example, if you develop a medicine that can treat diabetes and you desire FDA approval, the path is standardized and clearly laid out. For this paper, our contribution focused on the clinical evidence quality section and some of the clinical trial design components. In the U.S.,
Patients with conditions with limited treatment options could one day be cured by these breakthrough therapeutics, with treatments for everything from cancers, Parkinson’s and Alzheimer’s to strokes, spinal cord injuries and diabetes. We are all aligned and in frequent communication with each other.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content